Compare SMTI & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | EMBC |
|---|---|---|
| Founded | 1982 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.2M | 328.1M |
| IPO Year | 2008 | 2021 |
| Metric | SMTI | EMBC |
|---|---|---|
| Price | $35.05 | $5.89 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $35.00 | $4.00 |
| AVG Volume (30 Days) | 154.6K | ★ 898.0K |
| Earning Date | 11-11-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $14.23 | $5.59 |
| P/E Ratio | ★ N/A | $5.60 |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $2.77 |
| 52 Week High | $35.34 | $14.91 |
| Indicator | SMTI | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 63.39 | 61.46 |
| Support Level | $33.99 | $4.84 |
| Resistance Level | $35.34 | $5.91 |
| Average True Range (ATR) | 0.18 | 0.27 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 51.67 | 72.82 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.